<DOC>
	<DOC>NCT02552732</DOC>
	<brief_summary>The aim of this feasibility study is to provide data for a subsequent randomized controlled trial to investigate if patient outcomes will be improved after an acute COPD exacerbation using domiciliary nasal high flow therapy (NHF) compared to standard care. This feasibility study will investigate the following: process, resources, management and scientific aspects of delivering NHF as an adjunct therapy in COPD patients.</brief_summary>
	<brief_title>Nasal High Flow Therapy 30 Day Readmission Study</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>18 years of age or older Male and female Admitted to the respiratory ward(s) of either recruiting hospitals with AECOPD as the primary diagnostic reason for admission. Given a new home oxygen therapy prescription during the current hospital admission The investigator believes the participant or their care giver will be unable to safely use the myAIRVO 2 device following discharge They have any other condition which, at the investigator's discretion, is believed may present a safety risk or impact the feasibility of the study or the study results</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>